Wuhan Easy Diagnosis Biomedicine (002932) Stock Overview

Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, manufacture, and sale of in-vitro diagnostic products China and internationally. Its products portfolio includes molecular diagnostic products, such as PCR system, nucleic acid extraction and purification instrument, and sample release reagent; blood gas analyzer; immuno diagnosis, including chemiluminescence immunoassay, fluorescence immunity, and immunoquantitative analyzer; and automatic coagulation analyzer. The company also provides emergency and critical illness information solutions, including software, hardware, and certification consulting services; and third-party medical inspection services. It offers products in the areas of cardiovascular and cerebrovascular diseases, infectious diseases, kidney diseases, diabetes, infectious diseases, prenatal and postnatal care, health examination, thyroid, hormones, blood gas, coagulation, drug metabolism, pathogen detection, etc. Wuhan Easy Diagnosis Biomedicine Co.,Ltd. was founded in 2008 and is based in Wuhan, China.